Blockchain Registration Transaction Record

Creative Biolabs Integrates Microfluidics for Faster Antibody Discovery

Creative Biolabs integrates droplet generation all-in-one systems and customizable microfluidic chips for high-throughput antibody discovery and immune checkpoint research, accelerating biologics development.

This news matters because it addresses a critical bottleneck in biologics development: the need for efficient, scalable, and reproducible methods to discover therapeutic antibodies. By integrating droplet microfluidics with immune checkpoint research services, Creative Biolabs offers a pathway to accelerate the identification of high-quality antibody candidates, potentially reducing the time and cost of bringing new immunotherapies to patients. For researchers, this means faster lead selection, lower reagent costs, and more reliable data—key factors in an era where complex therapies like multispecific antibodies and cell-based immunotherapies are becoming increasingly common. Ultimately, advancements like these can speed the translation of basic research into life-saving treatments.